Skip to main content
TipRanks
Go Ultimate75% OFF

Agenus (AGEN) AI Stock Analysis

0 Followers
CH:AGEN

Agenus

(BX Swiss:AGEN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improving revenue and marginsThe latest results show substantial improvement in revenue and reported profitability, indicating stronger contribution from collaborations, licensing, or services. If Agenus can sustain this performance, higher margins could support reinvestment in its pipeline and reduce dependence on external financing over the next several quarters.
Negative Factors
Persistent cash burnAgenus remains far from self-funding, with operating and free cash flow materially negative after a multi-year pattern of burn. Continued development spending without sustained product revenue or substantial partnership economics increases reliance on financing and could constrain the pace of pipeline investment.

Agenus Business Overview & Revenue Model

Company Description

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expres...

Agenus Earnings Call Summary

Earnings Call Date:May 12, 2025(Q1-2025)|Next Earnings Date:Mar 16, 2027
Earnings Call SentimentNeutral

The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.

Positive Updates

Operational Efficiency Goals
Agenus is on track to reduce its operational cash burn to below $50 million annualized in the second half of 2025.

Negative Updates

Decrease in Cash Balance
The company ended Q1 2025 with a cash balance of $18.5 million, down from $40.4 million at the end of 2024.

Company Guidance

During Agenus Inc.'s First Quarter 2025 Earnings Conference Call, the company outlined several strategic priorities, focusing on their innovative BOT/BAL data, operational efficiencies, and impending transactions to enhance financial strength. They aim to reduce operational cash burn to below $50 million annually by the second half of 2025. The company's financials for the first quarter showcased a cash balance of $18.5 million, a reduction from $40.4 million at the end of 2024, with a net loss of $26.4 million or $1.03 per share. Revenue was reported at $24.1 million, primarily from non-cash royalty revenue. Agenus has received four transaction proposals, including a potential Emeryville facility sale and two BOT/BAL licensing deals, aimed to bolster their balance sheet. The call emphasized the wide-reaching potential of BOT/BAL in treating cold tumors, with promising data from recent studies, and discussed the evolving regulatory landscape that could expedite therapy approvals.

Agenus Risk Analysis

Agenus disclosed 87 risk factors in its most recent earnings report. Agenus reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Agenus Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:AGEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
INOINO55Neutral$262.23M-1.77-9999.00%―63.93%68.94%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ONCYONCY46Neutral$46.27M-1.22664.95%――11.90%
HURAHURA45Neutral$87.46M-2.71-146.80%――24.26%
SPROSPRO44Neutral$55.14M-1.92-75.22%―36.15%38.57%
TILTIL42Neutral$39.00M-1.85-19.26%――72.92%

* Healthcare Sector Average

Performance Comparison

-50%0%50%INOONCYHURASPROTILDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:AGEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
INOInovio Pharmaceuticals1.63-0.15-8.43%
ONCYOncolytics Biotech0.38-0.66-63.27%
HURATuhura Biosciences, Inc.1.40-0.35-20.00%
SPROSpero Therapeutics0.90-1.48-62.14%
TILInstil Bio, Inc.5.40-6.80-55.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.